ADC Therapeutics SA (NYSE: ADCT) opened the trading session on February 24, 2022, at $15.17, illustrating a change of 5.4592% versus the previous close at $15.57. During the trading session, the stock price jumped to $16.51 and sunk to $14.97. Finally, the stock stabilized at $16.42. However, given a distant prospect, ADC Therapeutics SA reported a 52 Week Range between $13.34-$32.
ADC Therapeutics SA's shares outstanding currently worth $76.72M, concurrently with a float of $0. ADCT operates in the TECHNOLOGY sector of the GENERAL industry and has a market capitalization of $1.26B (as of February 24, 2022). It's worth mentioning that ADC Therapeutics SA's 50-day Moving Average stabilized at $17.8, while such sign as 200-day Moving Average is presently $22.98.
To measure the company's efficiency, let's consider ADC Therapeutics SA's conglomerate performance. Till now, ADCT has full-time employees. ADC Therapeutics SA has generated $nan per worker During the last fiscal year. In the interim, ADCT's income per employee was $inf. And now, let's consider the company's income report. ADC Therapeutics SA's Net Income for the last fiscal year was $-246,290,000, while such sign as Income Before Taxes was at the level of $-245,963,000. ADCT's Operating Income was at the mark of $-219,263,000.
ADC Therapeutics SA (ADCT) Earnings & Revenue
Talking about the Profitability, ADCT reached a Profit Margin of 0% and an Operating Margin (TTM) of -1637%. However, when we touch the questions of management effectiveness, ADC Therapeutics SA generated a Return on Equity (TTM) of -89.3% and a Return on Assets (TTM) of -29.8%. A bit more income statements might bring clarity to our overview. According to the results of the latest quarter ended September 30, 2021, ADC Therapeutics SA generated Revenue (TTM) of $16.91M, reporting a Quarterly Revenue Growth of -100%. As for the Revenue Per Share (TTM), this indicator was at the mark of $0.22. The company's Gross Profit (TTM) was $-141,816,000, while according to the EBITDA report, it was estimated at $.
ADC Therapeutics SA (NYSE: ADCT) Owners & Shares
Finally, let's take a look at the share statistics. As mentioned above, ADCT's shares outstanding now amounts to $76.72M, where Shares Short was $0 versus the prior month amounted to $0. (Short % of Float was 0%). And now, let's overview which kind of investors works with ADC Therapeutics SA's stocks. ADCT's current ownership accounts for % institutional investors, while % of shares belong to the insiders. Also worth mentioning some indicators affecting dividends & splits. Thus, ADCT's Forward Annual Dividend Rate is currently at the mark of , whereas the Dividend Yield is 0%, and a Dividend Payout Ratio is 0% (Dividend Date: December 31, 1969). The company's Dividend Per Share sign thereby is $0.
ADCT Trading Performance
It's time to observe the current performance indicators for ADC Therapeutics SA. ADCT's price/earnings to growth ratio during the last reported quarter was 0%. The company's PE Ratio stands at None%, while ADCT's Beta score is None. Also worth noting that ADC Therapeutics SA's Diluted EPS (Earnings per Share) trailing twelve months is at the mark of -3.278. Other valuable indicators are Price To Sales Ratio (TTM), which is currently recorded at 74.51, as well as Price To Book Ratio, which amounts to 6.23.
ADC Therapeutics SA Analysis & Estimates
Within the previous 9-day period, ADC Therapeutics SA's Average True Range (ATR) was 1.0421, while the stock's Stochastic SlowD moving average was 72.3894%, and the SlowK moving average volumed at 72.3894%.